EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Repurposing Amphotericin B and Its Liposomal Formulation for the Treatment of Human Mpox

Daniela Peruzzu iD, Katia Fecchi, Giulietta Venturi iD, Maria Cristina Gagliardi

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24108896 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Daniela Peruzzu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Center for Gender-Specific Medicine, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy. Hauptthemen laut MEDLINE: Mpox, Monkeypox, Sexual and Gender Minorities. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mpox (monkeypox) is a zoonotic viral disease caused by the mpox virus (MPXV). Recently in 2022, a multi-country Mpox outbreak has determined great concern as the disease rapidly spreads. The majority of cases are being noticed in European regions and are unrelated to endemic travel or known contact with infected individuals. In this outbreak, close sexual contact appears to be important for MPXV transmission, and an increasing prevalence in people with multiple sexual partners and in men who have sex with men has been observed. Although Vaccinia virus (VACV)-based vaccines have been shown to induce a cross-reactive and protective immune response against MPXV, limited data support their efficacy against the 2022 Mpox outbreak. Furthermore, there are no specific antiviral drugs for Mpox. Host-cell lipid rafts are small, highly dynamic plasma-membrane microdomains enriched in cholesterol, glycosphingolipids and phospholipids that have emerged as crucial surface-entry platforms for several viruses. We previously demonstrated that the antifungal drug Amphotericin B (AmphB) inhibits fungal, bacterial and viral infection of host cells through its capacity to sequester host-cell cholesterol and disrupt lipid raft architecture. In this context, we discuss the hypothesis that AmphB could inhibit MPXV infection of host cells through disruption of lipid rafts and eventually through redistribution of receptors/co-receptors mediating virus entry, thus representing an alternative or additional therapeutic tool for human Mpox.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mpox, MonkeypoxSexual and Gender MinoritiesMaleAnimalsHumansAmphotericin BDrug RepositioningHomosexuality, MaleZoonosesLiposomesPhenylbutyrates

Stichwörter der Autor:innen

Amphotericin BMpox (monkeypox)drug repurposinglipid rafts

Substanzen

Amphotericin BLiposomes2-aminomethyl-4-(4-chlorophenyl)-4-hydroxybutyric acidPhenylbutyrates

Autor:innen und Institutionen

  • Center for Gender-Specific Medicine, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy.
  • Department of Infectious Diseases, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy.

ORCID-Profile: Daniela Peruzzu, Giulietta Venturi

Zitieren

APA

Peruzzu, D., Fecchi, K., Venturi, G., & Gagliardi, M. C. (2023). Repurposing Amphotericin B and Its Liposomal Formulation for the Treatment of Human Mpox. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24108896

Vancouver

Peruzzu D, Fecchi K, Venturi G, Gagliardi MC. Repurposing Amphotericin B and Its Liposomal Formulation for the Treatment of Human Mpox. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24108896

BibTeX
@article{Peruzzu2023,
  author = {Peruzzu, Daniela and Fecchi, Katia and Venturi, Giulietta and Gagliardi, Maria Cristina},
  title = {Repurposing Amphotericin B and Its Liposomal Formulation for the Treatment of Human Mpox},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24108896}
}
Kostenlos starten →